《公司業績》綠葉製藥(02186.HK)半年純利3.87億元人民幣跌28.3%
綠葉製藥(02186.HK)公佈截至今年6月底止中期業績,營業額29.52億元人民幣(下同),按年跌0.4%。純利3.87億元,按年跌28.3%;每股盈利11.32分。不派息。
期間,集團來自心血管系統產品的銷售收入增加86.4%至8.01億元。來自消化與代謝產品的銷售收入增加17.1%至4.58億元。來自腫瘤科產品的銷售收入減少30.5%至9.27億元。來自中樞神經系統產品的銷售收入減少7.0%至6.94億元。
6月30日,集團 擁有33項處於不同發展階段的中國在研產品。該等在研藥物包括13種腫瘤產品、13種中樞神經系統產品及7種其他產品。
此外,集團在美國、歐洲和日本擁有13種處於不同開發階段的在研產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.